CN114848750A - Traditional Chinese medicine composition for improving immunity - Google Patents
Traditional Chinese medicine composition for improving immunity Download PDFInfo
- Publication number
- CN114848750A CN114848750A CN202210662663.4A CN202210662663A CN114848750A CN 114848750 A CN114848750 A CN 114848750A CN 202210662663 A CN202210662663 A CN 202210662663A CN 114848750 A CN114848750 A CN 114848750A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- water
- extracting
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 230000036039 immunity Effects 0.000 title claims abstract description 14
- 241000222336 Ganoderma Species 0.000 claims abstract description 49
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 230000007812 deficiency Effects 0.000 claims abstract description 14
- 230000036737 immune function Effects 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 230000001105 regulatory effect Effects 0.000 claims abstract description 10
- 230000004060 metabolic process Effects 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 239000000843 powder Substances 0.000 claims description 24
- 238000009835 boiling Methods 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 16
- 240000008397 Ganoderma lucidum Species 0.000 claims description 14
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 13
- 238000007873 sieving Methods 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 238000002791 soaking Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000001694 spray drying Methods 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 240000002948 Ophiopogon intermedius Species 0.000 claims 2
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 210000001835 viscera Anatomy 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 description 25
- 244000248557 Ophiopogon japonicus Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229930195210 Ophiopogon Natural products 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000038022 Chenopodium capitatum Species 0.000 description 1
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001448424 Ophiopogon Species 0.000 description 1
- 241001448421 Ophiopogon jaburan Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- -1 and can consume qi Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930190017 ophiopogonin Natural products 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for improving immunity, which is prepared from the following raw material medicines in parts by weight: 1-5 parts of radix ophiopogonis and 1-5 parts of lucid ganoderma. The invention also provides a preparation method and application of the composition. The composition provided by the invention is reasonable in compatibility, has good effects of improving the immune function, improving the deficiency of five internal organs and regulating metabolism, is simple in preparation method and convenient to use, and provides a treatment and health-care product choice.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a traditional Chinese medicine composition with the functions of improving the immunity of people, improving the deficiency of five internal organs and regulating metabolism.
Background
Immunity refers to the ability of the human body to recognize and treat damaged, aged, denatured, dead and mutated cells in the body and virus-infected cells, and is a defense mechanism of the human body to recognize and eliminate foreign bodies such as foreign viruses and bacteria. When the immune system performing this mechanism in the human body fails to function normally under the influence of various reasons, the human body is infected by foreign materials such as viruses and bacteria, so that the most direct common clinical manifestation of patients with low immunity is that they are susceptible to diseases. When the body is frequently over-consumed, the symptoms of weak constitution, easy fatigue, poor energy, decreased resistance and the like can appear.
In traditional Chinese medicine, the basic principle of strengthening body resistance and consolidating constitution is taken as a basic rule for treating diseases, and the immune function of a patient is improved and the immunity level of the patient is improved by regulating the balance of yin and yang of qi and blood of internal organs. The patent CN110025011A discloses an ophiopogon root ginseng buccal tablet for enhancing immunity, which improves the utilization rate of raw materials by optimizing an extraction process, and achieves the effect of obviously improving the immunity by only using two medicines of ginseng and ophiopogon root. Because the Chinese patent medicine can be obtained by a specific process, the cost is high, the compliance of patients is poor, and the clinical popularization and application are not facilitated.
Disclosure of Invention
In order to solve the problems, the invention provides a traditional Chinese medicine composition for improving immunity, which is prepared from the following raw material medicines in parts by weight:
1-5 parts of radix ophiopogonis and 1-5 parts of lucid ganoderma.
Further, the traditional Chinese medicine is prepared from the following raw material medicines in parts by weight:
3 parts of dwarf lilyturf tuber and 3 parts of lucid ganoderma.
Furthermore, the preparation is prepared by taking the raw powder or water or organic solvent extract of the dwarf lilyturf tuber and the lucid ganoderma as active ingredients and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
Still further, the formulation is an oral formulation.
Still further, the oral formulation is a tablet, solution, pill, paste or powder, preferably a tablet.
The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
a. weighing the raw material medicines in the weight ratio;
b. the raw materials are directly pulverized, or extracted by adding water or organic solvent, and added with food or pharmaceutically acceptable adjuvants or auxiliary components.
Further, in the bulk drug in the step b,
pulverizing radix ophiopogonis and 1/2-4/5 weight parts of lucid ganoderma into powder, soaking in water, boiling and extracting for three times, combining extracting solutions, concentrating and drying to obtain an extract; pulverizing the rest Ganoderma to obtain powder; mixing the extract and powder, and adding food or pharmaceutically acceptable adjuvants or auxiliary components.
Further, the soaking time is 0-1 h; preferably, the soaking time is 0.5 h;
during boiling extraction, adding 8-15 times of water for the first time, and extracting for 1-2 h; adding 8-15 times of water for the second time, and extracting for 1-2 h; adding 8-15 times of water for the third time, and extracting for 1-2 h; preferably, 15 times of water is added for the first time, and the extraction is carried out for 1 h; adding 10 times of water for the second time, and extracting for 1 h; adding 8-10 times of water for the third time, and extracting for 1 h;
the concentration is reduced pressure concentration, the vacuum degree is-0.04 to-0.08 mpa, the temperature is 60 to 80 ℃, and the concentration is carried out until the relative density is 1.08 to 1.15; preferably, the concentration temperature is 60 ℃, and the concentration is carried out until the relative density is 1.10-1.12;
the drying is spray drying, the air inlet temperature is 180-; preferably, the air inlet temperature is 200 ℃, and the air outlet temperature is 100 ℃;
sieving the powder with a sieve of 80-500 meshes; preferably, the sieve is 150-200 meshes.
The invention also provides application of the composition in preparing a medicament or food with the effects of improving the immunity of people, improving the deficiency of five internal organs and regulating metabolism.
Further, the food is an immunomodulatory health food.
In the composition, the radix ophiopogonis, the name of the traditional Chinese medicine, is dried root tuber of Ophiopogon japonica (L.f) Ker-Gawl. of lilyturf root of Liliaceae. Collected in summer, cleaned, repeatedly exposed to the sun, piled until the seven-eight dry, removed fibrous root, and dried. Sweet, slightly bitter and slightly cold in nature. Has effects of nourishing yin, promoting fluid production, moistening lung and clearing heart fire, and can be used for treating lung dryness, dry cough, yin deficiency tuberculosis cough, pharyngitis, pharyngalgia, body fluid consumption thirst, internal heat diabetes, vexation, insomnia, and constipation due to intestinal dryness. Modern pharmacological research shows that the compound mainly contains ophiopogonin, steroid saponin, alkaloid, sitosterol, glucose, amino acid, vitamin and the like, and has the effects of resisting fatigue, eliminating free radicals, improving the cellular immune function and reducing blood sugar. However, Mai Dong is cold in nature and should not be taken for a long time, and people with phlegm-damp constitutions and deficiency-cold of spleen and stomach should be cautioned.
Ganoderma lucidum, a traditional Chinese medicine name, is dried fruiting body of Ganoderma lucidum Ganoderma lucidum (Leys. ex Fr.) Karst. Harvesting all year round, removing impurities, cutting off lower stipe attached with rotten wood, silt or culture medium, and drying in shade or oven drying at 40-50 deg.C. Sweet in nature and mild in nature. Has effects of invigorating qi, tranquilizing mind, relieving cough and asthma, and can be used for treating restlessness of heart-mind, insomnia, palpitation, cough and asthma due to lung deficiency, asthenia, short breath, and anorexia. Research shows that the compound has good immunoregulation function, has recovery effect on both specific and non-specific immune functions, and has good application value in immune function regulation. However, Ganoderma lucidum is sweet and warm, so it is not suitable for patients with excess syndrome, and it also promotes pathogenic qi to make the disease worse when it is eaten at the beginning of exogenous disease.
The compatibility and prescription of the traditional Chinese medicines are based on the differentiation of yin and yang, cold and heat, deficiency and excess, and the medicines are used for strengthening body resistance and eliminating pathogenic factors, so the cold medicines and the heat medicines are not combined and used together generally, and the medicine effect is reduced. Earlier experiments show that the compatibility of ophiopogon root and lucid ganoderma has large difference in the regulating action on the immune function when the dosage is different, and even the effects of improving the immune function, improving the deficiency of five internal organs and regulating the metabolism can not be achieved.
The compatibility of the two medicines is precise and appropriate, and in the formula, the radix ophiopogonis is sweet and cold and the lucid ganoderma is sweet and warm; ophiopogon root, radix ophiopogonis, lucid ganoderma and radix ophiopogonis, wherein the ophiopogon root is used for nourishing yin and tonifying qi; radix Ophiopogonis has heart-fire clearing away, and Ganoderma has mind tranquilizing effect; mai Dong moistens lung and Ganodorma lucidum can stop cough. The two herbs are combined with each other, and have the effects of combining cold and warm, tonifying without stagnation, no heat generation, and no fear of stomach injury due to nourishing, and can be used for treating cold, heat, deficiency and excess.
Animal experiments prove that the specific dosage of the radix ophiopogonis and the ganoderma lucidum in the invention has obvious treatment and health care effects on improving the immunity of people, improving the deficiency of five internal organs and regulating metabolism. In addition, the radix ophiopogonis and lucid ganoderma with the specific proportion are also particularly suitable for patients with tumor radiotherapy and chemotherapy, most of radiotherapy and chemotherapy drugs are warm and toxic products, and can consume qi, blood and body fluid of a human body to generate a plurality of symptoms.
The composition is prepared by a scientific method, is safe and reliable, has the synergistic effect of supplementing the raw materials, can obviously improve the immunity of the organism, improve the deficiency of the five internal organs and regulate the metabolism, has a simple preparation method and convenient use, and provides a traditional Chinese medicine adjuvant therapy and health-care product selection.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Detailed Description
EXAMPLE 1 preparation of a composition according to the invention
The formula is as follows: 300g of dwarf lilyturf tuber and 300g of lucid ganoderma.
The preparation method comprises the following steps:
first, pretreatment
1) Respectively taking radix Ophiopogonis and Ganoderma, and removing impurities.
2) Taking 300g of radix ophiopogonis medicinal material and 200g of ganoderma lucidum medicinal material, and coarsely crushing (20 meshes); 100g of lucid ganoderma medicinal material is taken, crushed and sieved by a 200-mesh sieve to obtain fine powder.
Second, extraction and concentration
1) Extracting the ganoderma lucidum and the radix ophiopogonis: soaking 300g of radix Ophiopogonis and 200g of Ganoderma coarse powder in 15 times of water for 0.5h, boiling and extracting for 1h, filtering the extractive solution, collecting filtrate, adding 10 times of water into the residue, boiling and extracting for 1h, filtering the extractive solution, and mixing the three extractive solutions.
2) Concentration: concentrating the lucid ganoderma and dwarf lilyturf tuber extracting solution by adopting a reduced pressure concentration method (the vacuum degree is-0.04 to-0.08 mpa, the concentration temperature is 60 ℃) until the relative density is 1.10.
3) Spray drying: drying the Ganoderma and radix Ophiopogonis concentrated solution by spray drying at air inlet temperature of 200 deg.C and air outlet temperature of 100 deg.C.
Thirdly, mixing and granulating
Mixing the extracts of Ganoderma and radix Ophiopogonis with Ganoderma fine powder and microcrystalline cellulose, stirring, wet granulating with 80% ethanol, and sieving with 20 mesh sieve.
Drying and granulating
Drying the prepared wet granules at 60 ℃ until the moisture content is less than or equal to 5%, taking out, cooling to room temperature, and sieving with a 14-mesh sieve for finishing granules.
Fifth, tabletting
0.5 percent of magnesium stearate is added into the granules, and the granules are tableted and coated to obtain 0.5 g of granules.
Example 2 preparation of a composition according to the invention
The formula is as follows: 500g of dwarf lilyturf tuber and 200g of lucid ganoderma.
The preparation method comprises the following steps:
first, pretreatment
1) Respectively taking radix Ophiopogonis and Ganoderma, and removing impurities.
2) Taking 500g of radix ophiopogonis medicinal material and 100g of ganoderma lucidum medicinal material, and coarsely crushing (20 meshes); 100g of lucid ganoderma medicinal material is taken, crushed and sieved by a 200-mesh sieve to obtain fine powder.
Second, extraction and concentration
1) Extracting the ganoderma lucidum and the radix ophiopogonis: soaking 500g of radix Ophiopogonis and 100g of Ganoderma coarse powder in 15 times of water for 0.5 hr, boiling and extracting for 1 hr, filtering the extractive solution, collecting filtrate, adding 10 times of water into the residue, boiling and extracting for 1 hr, filtering the extractive solution, collecting filtrate, adding 8 times of water into the residue, boiling and extracting for 1 hr, filtering the extractive solution, and mixing the three extractive solutions.
2) Concentration: concentrating the lucid ganoderma and dwarf lilyturf tuber extracting solution by adopting a reduced pressure concentration method (the vacuum degree is-0.04 to-0.08 mpa, the concentration temperature is 60 ℃) until the relative density is 1.12.
3) Spray drying: drying the Ganoderma and radix Ophiopogonis concentrated solution by spray drying at air inlet temperature of 200 deg.C and air outlet temperature of 100 deg.C.
Thirdly, mixing and granulating
Mixing the extracts of Ganoderma and radix Ophiopogonis with Ganoderma fine powder and microcrystalline cellulose, stirring, wet granulating with 80% ethanol, and sieving with 20 mesh sieve.
Drying and granulating
Drying the prepared wet granules at 60 ℃ until the moisture content is less than or equal to 5%, taking out, cooling to room temperature, and sieving with a 14-mesh sieve for finishing granules.
Fifth, tabletting
0.5 percent of magnesium stearate is added into the granules, and the granules are tableted and coated to obtain 0.5 g of granules.
EXAMPLE 3 preparation of the composition of the invention
The formula is as follows: 200g of dwarf lilyturf tuber and 500g of lucid ganoderma.
The preparation method comprises the following steps:
first, pretreatment
1) Respectively taking radix Ophiopogonis and Ganoderma, and removing impurities.
2) Coarsely pulverizing 200g radix Ophiopogonis and 400g Ganoderma (20 mesh); 100g of lucid ganoderma medicinal material is taken, crushed and sieved by a 150-mesh sieve to obtain fine powder.
Second, extraction and concentration
1) Extracting the ganoderma lucidum and the radix ophiopogonis: soaking 200g of radix Ophiopogonis and 400g of Ganoderma coarse powder in 15 times of water for 0.5 hr, boiling and extracting for 1 hr, filtering the extractive solution, collecting filtrate, adding 10 times of water into the residue, boiling and extracting for 1 hr, filtering the extractive solution, collecting filtrate, adding 8 times of water into the residue, boiling and extracting for 1 hr, filtering the extractive solution, and mixing the three extractive solutions.
2) Concentration: concentrating the lucid ganoderma and dwarf lilyturf tuber extracting solution by adopting a reduced pressure concentration method (the vacuum degree is-0.04 to-0.08 mpa, the concentration temperature is 60 ℃) until the relative density is 1.10.
3) Spray drying: drying the Ganoderma lucidum and radix Ophiopogonis concentrated solution by spray drying at air inlet temperature of 200 deg.C and air outlet temperature of 100 deg.C.
Thirdly, mixing and granulating
Mixing the extracts of Ganoderma and radix Ophiopogonis with Ganoderma fine powder and microcrystalline cellulose, stirring, wet granulating with 80% ethanol, and sieving with 20 mesh sieve.
Drying and granulating
Drying the prepared wet granules at 60 ℃ until the moisture content is less than or equal to 5%, taking out, cooling to room temperature, and sieving with a 14-mesh sieve for finishing granules.
Fifth, tabletting
0.5 percent of magnesium stearate is added into the granules, and the granules are tableted and coated to obtain 0.5 g of granules.
The beneficial effects of the invention are illustrated by way of test examples as follows:
test example 1 efficacy test of the composition of the present invention for enhancing immune function and improving the deficiency of five organs
1. Test drug
Example preparation of sample a: sample A in the examples was prepared according to the recipe 50g of Ophiopogon japonicus and 550g of Ganoderma lucidum. Soaking 50g of radix Ophiopogonis and 450g of Ganoderma coarse powder in 15 times of water for 0.5 hr, boiling and extracting for 1 hr, filtering the extractive solution, collecting filtrate, adding 10 times of water into the residue, boiling and extracting for 1 hr, filtering the extractive solution, collecting filtrate, adding 8 times of water into the residue, boiling and extracting for 1 hr, filtering the extractive solution, and mixing the three extractive solutions. Concentrating the extractive solution of Ganoderma and radix Ophiopogonis by vacuum concentration (vacuum degree of-0.04-0.08 mpa, concentration temperature of 60 deg.C) to relative density of 1.10. Drying the Ganoderma lucidum and radix Ophiopogonis concentrated solution by spray drying at air inlet temperature of 200 deg.C and air outlet temperature of 100 deg.C. Mixing the extracts with 100g Ganoderma fine powder and microcrystalline cellulose, stirring, wet granulating with 80% ethanol, and sieving with 20 mesh sieve. Drying the prepared wet granules at 60 ℃ until the moisture content is less than or equal to 5%, taking out, cooling to room temperature, and sieving with a 14-mesh sieve for finishing granules. 0.5 percent of magnesium stearate is added into the granules, and the granules are tableted and coated to obtain 0.5 g of granules.
Example preparation of sample B except: sample B in the examples was prepared according to the recipe 550g of Ophiopogon japonicus and 50g of Ganoderma lucidum. Soaking 550g of radix Ophiopogonis and 50g of Ganoderma coarse powder in 15 times of water for 0.5 hr, boiling and extracting for 1 hr, filtering the extractive solution, collecting filtrate, adding 10 times of water into the residue, boiling and extracting for 1 hr, filtering the extractive solution, collecting filtrate, adding 8 times of water into the residue, boiling and extracting for 1 hr, filtering the extractive solution, and mixing the three extractive solutions. Concentrating the lucid ganoderma and dwarf lilyturf tuber extracting solution by adopting a reduced pressure concentration method (the vacuum degree is-0.04 to-0.08 mpa, the concentration temperature is 60 ℃) until the relative density is 1.10. Drying the Ganoderma and radix Ophiopogonis concentrated solution by spray drying at air inlet temperature of 200 deg.C and air outlet temperature of 100 deg.C. Mixing the extracts of Ganoderma and radix Ophiopogonis with microcrystalline cellulose, stirring, wet granulating with 80% ethanol, and sieving with 20 mesh sieve. Drying the prepared wet granules at 60 ℃ until the moisture content is less than or equal to 5%, taking out, cooling to room temperature, and sieving with a 14-mesh sieve for finishing granules. 0.5 percent of magnesium stearate is added into the granules, and the granules are tableted and coated to obtain 0.5 g of granules.
2. Method of producing a composite material
SPF male Balb/c mice weighing 18g-22g were selected, and 6 groups of the drugs prepared in examples 1, 2 and 3 and the drugs prepared in example A and example B were divided into 10 groups of control groups. (1) The dose of the drug group is 2.25g/kg, and the stomach is drenched continuously for 30 days. (2) Control group: and (5) infusing normal saline with equal dosage, and continuously infusing the stomach for 30 days. And measuring various functional indexes of the mouse after the last gastric lavage.
3. Results
And after the continuous gavage for 30 days, weighing the weight of the animal, killing the animal by neck pushing and dislocation, taking out the spleen and the thymus, and weighing the spleen and the thymus respectively. Compared with the control group mice, the spleen/body weight ratio and the thymus/body weight ratio of each dose group have no significant difference (P >0.05) (Table 1), which indicates that the tested substances have no influence on the organs of the mice.
TABLE 1 Effect on organ/body weight ratio in mice
At the 25 th day of continuous gavage, each mouse was injected intraperitoneally with 0.2ml of 2% (v/v) SRBC, and after continuing gavage for 4 days, the thickness of the left hind plantar aspect was measured, 3 measurements were taken for averaging, and then 20% (v/v) SRBC, each 20ul, was injected subcutaneously at the measurement site. The thickness of the left hind foot sole was measured 24h after injection and 3 measurements were averaged. The difference in thickness of the plantar aspect of the foot before and after the attack is calculated. At 24h after antigen challenge, the swelling degree of the foot plantar swelling of the example group is significantly different compared with the control group of mice (P <0.05), while the swelling degree of the foot plantar swelling of the example group is not significantly different compared with the control group of mice (P >0.05), which is shown in Table 2. The pharmaceutical composition of the invention is helpful for increasing the humoral immunity of the body.
TABLE 2 Effect on delayed allergy (DTH) in mice
Denotes P <0.05 compared with control group
On the 25 th day of continuous lavage, injecting 0.2ml of 2% (v/v) SRBC into the abdominal cavity of each mouse for immunization, continuously performing lavage for 5 days, removing eyeballs, taking blood in a centrifugal tube, placing for 1h, stripping, centrifuging at 2000r/min for 10min, collecting serum, diluting the serum by using physiological saline in a multiple ratio manner, diluting 12 holes in each part, placing blood with different dilutions in a blood coagulation plate with 100ul in each hole, adding 100ul of 0.5% (v/v) SRBC suspension, mixing uniformly, placing in a wet box for 3h at 37 ℃, observing the result, and recording the agglutination degree of each hole. And (5) calculating the volume of the antibody. The results show that the antibody product numbers of the example groups are all significantly different (P <0.05) compared with the control group mice, and the antibody product numbers of the example exception sample groups are all significantly different (P >0.05) compared with the control group mice, respectively, as shown in Table 3. The pharmaceutical composition of the invention is helpful for increasing the cellular immunity of the body.
TABLE 3 Effect on the number of mouse serum hemolysin antibodies
Denotes P <0.05 compared with control group
After continuous gavage for 30 days, 0.0lml/g of Indian ink diluted 1:4 is injected from mouse tail vein, and 20ul of blood is taken from mouse inner peripheral vein at 2min and 10min respectively and added to Na solution containing 2ml of 1mg/ml 2 CO 3 The solution was mixed in a test tube, and OD was measured at 600nm wavelength using a spectrophotometer (using 1mg/ml Na) 2 CO 3 Solution as blank). The results showed that the phagocytic index α of the mice in the examples was significantly different from that of the control mice ((P)<0.01，P<0.05，P<0.05), see table 4. The pharmaceutical composition of the invention is useful for increasing the monocyte-macrophage activity of the body.
TABLE 4 Effect on mouse carbon clearance
P <0.05 compared to control; represents P < 0.01 compared with control group
After 30 days of continuous gavage, the animals were sacrificed by dislocation of cervical vertebrae, the spleen was taken out, shredded, sieved through a 200-mesh sieve, and washed with Hank's solution3 times, using complete 1640 culture solution to prepare 2X 10 6 Cell suspension// ml. 300ul of each mouse cell suspension was placed in a 96-well plate with 100ul per well and target cells (YAC-1 cells, 4X 10 cells) per well 5 One per ml) of the cells are 100ul, and simultaneously, a natural release hole (100 ul of the target cells and 100ul of culture solution) and a maximum release hole (100 ul of the target cells and 8 holes of 1% NP-40100 ul of each cell are made, 5% CO is added at 37 DEG C 2 Culturing for 4h, taking out 1500r/min, and centrifuging for 5 min. 100ul of supernatant from each well was placed in another plate, 100ul of matrix solution was added to each well, 1mol/L HCl 30ul was added after 10min to stop the reaction, and OD was measured at 490 nm. Calculating the activity rate of NK cells. The results showed that the NK cell activity rates of the mice in the examples were significantly different from those of the control group (P)<0.05), see table 5. The pharmaceutical composition of the invention is helpful for increasing the activity of NK cells of the body.
TABLE 5 Effect on NK cell Activity in mice
P <0.05 compared to control;
the pharmaceutical composition can obviously improve the humoral immunity and the cellular immunity of mice and increase the activity of mononuclear-macrophage and NK cells, thereby playing the roles of improving the immune function of organisms, improving the deficiency of five internal organs and regulating the metabolism.
In conclusion, the radix ophiopogonis and the lucid ganoderma in the composition have long medicinal ingredients, but the immune regulation effect of the prescription can be changed by slight change of the dosage, when 1-5 parts of radix ophiopogonis and 1-5 parts of lucid ganoderma are matched, particularly 1 part of radix ophiopogonis and 1 part of lucid ganoderma are matched, the composition is compatible in yin and yang, cold and warm, has the effects of Qin and Se combination, is inserted into threads, is tonifying without stagnation, does not have the disadvantage of generating heat, does not have the worry of polluting stomach, is mild in nature, can be applied to cold and heat deficiency and excess, can be used for improving the immune function of people, improving the five internal organs deficiency and regulating the metabolism, and has remarkable treatment and health care effects.
Claims (10)
1. A traditional Chinese medicine composition for improving immunity is characterized in that: the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
1-5 parts of radix ophiopogonis and 1-5 parts of lucid ganoderma.
2. The traditional Chinese medicine composition according to claim 1, characterized in that: the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
3 parts of dwarf lilyturf tuber and 3 parts of lucid ganoderma.
3. The traditional Chinese medicine composition according to claim 1 or 2, wherein: the preparation is prepared by taking raw powder or water or organic solvent extract of dwarf lilyturf tuber and lucid ganoderma as active ingredients and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
4. The traditional Chinese medicine composition according to claim 3, wherein: the preparation is an oral preparation.
5. The traditional Chinese medicine composition according to claim 4, wherein: the oral preparation is tablet, solution, pill, paste or powder, preferably tablet.
6. The method for preparing the traditional Chinese medicine composition of any one of claims 1 to 5, which is characterized in that: it comprises the following steps:
a. weighing the raw material medicines in the weight ratio;
b. the raw materials are directly pulverized, or extracted by adding water or organic solvent, and added with food or pharmaceutically acceptable adjuvants or auxiliary components.
7. The method of claim 6, wherein: b, pulverizing radix ophiopogonis and 1/2-4/5 weight parts of ganoderma lucidum into powder, soaking in water, boiling and extracting for three times, combining extracting solutions, concentrating and drying to obtain an extract; pulverizing the rest Ganoderma to obtain powder; mixing the extract and powder, and adding food or pharmaceutically acceptable adjuvants or auxiliary components.
8. The method of claim 7, wherein: the soaking time is 0-1 h; preferably, the soaking time is 0.5 h;
during boiling extraction, adding 8-15 times of water for the first time, and extracting for 1-2 h; adding 8-15 times of water for the second time, and extracting for 1-2 h; adding 8-15 times of water for the third time, and extracting for 1-2 h; preferably, 15 times of water is added for the first time, and the extraction is carried out for 1 h; adding 10 times of water for the second time, and extracting for 1 h; adding 8-10 times of water for the third time, and extracting for 1 h;
the concentration is reduced pressure concentration, the vacuum degree is-0.04 to-0.08 mpa, the temperature is 60 to 80 ℃, and the concentration is carried out until the relative density is 1.08 to 1.15; preferably, the concentration temperature is 60 ℃, and the concentration is carried out until the relative density is 1.10-1.12;
the drying is spray drying, the air inlet temperature is 180-; preferably, the air inlet temperature is 200 ℃, and the air outlet temperature is 100 ℃;
sieving the powder with a sieve of 80-500 meshes; preferably, the mixture is sieved by a sieve of 150-200 meshes.
9. Use of the composition of any one of claims 1-5 in the preparation of a medicament or food for enhancing immune function, improving the five-organ deficiency, and regulating metabolism in a human.
10. Use according to claim 9, characterized in that: the food is an immunoregulatory health food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210662663.4A CN114848750A (en) | 2022-06-13 | 2022-06-13 | Traditional Chinese medicine composition for improving immunity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210662663.4A CN114848750A (en) | 2022-06-13 | 2022-06-13 | Traditional Chinese medicine composition for improving immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114848750A true CN114848750A (en) | 2022-08-05 |
Family
ID=82623851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210662663.4A Pending CN114848750A (en) | 2022-06-13 | 2022-06-13 | Traditional Chinese medicine composition for improving immunity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114848750A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116035207A (en) * | 2022-12-07 | 2023-05-02 | 四川省川麦冬产业发展有限公司 | A paste food containing radix Ophiopogonis fibrous root extract for enhancing immunity |
-
2022
- 2022-06-13 CN CN202210662663.4A patent/CN114848750A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 宋敬东, 天津科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116035207A (en) * | 2022-12-07 | 2023-05-02 | 四川省川麦冬产业发展有限公司 | A paste food containing radix Ophiopogonis fibrous root extract for enhancing immunity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101513437B (en) | Antifatigue Chinese pharmaceutical composition and preparation method thereof | |
| CN106606529A (en) | Composition with auxiliary blood sugar reduction efficacy, and preparation method and application thereof | |
| CN106072578A (en) | There is the enhancing enzyme composition of immune function of human body, effervescent tablet and preparation method | |
| CN106174485A (en) | There is the enzyme composition of kidney-reinforcing Yang strengthening effect, effervescent tablet and preparation method | |
| CN106806853B (en) | Traditional Chinese medicine composition for relieving physical fatigue and/or improving anoxia endurance, preparation method and application thereof | |
| CN103155985B (en) | Rhizoma polygonati nutrition powder and preparation method thereof | |
| CN108813610B (en) | Saussurea involucrate composition for improving immunity and application thereof | |
| CN112915181B (en) | Qi-tonifying and vitality-restoring cream formula and application thereof | |
| CN100574768C (en) | A kind of anticancer pharmaceutical composition and its production and use | |
| CN114848750A (en) | Traditional Chinese medicine composition for improving immunity | |
| CN113209166A (en) | Anti-aging traditional Chinese medicine composition containing nicotinamide mononucleotide and preparation method thereof | |
| CN108066384A (en) | A kind of Chinese medicine preparation with strengthen immunity and preparation method thereof | |
| CN105902827A (en) | Traditional Chinese medicine composition for improving immunity of human body and preparation method thereof | |
| CN115869370A (en) | A Chinese medicinal composition for treating sunken atmosphere diseases, and its preparation method | |
| CN112494569B (en) | Traditional Chinese medicine composition for improving immunity and preparation method and application thereof | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN111329968A (en) | Selenium-enriched agaricus blazei murill and ash tree flower tablet and preparation method thereof | |
| CN106074710A (en) | A kind of medicine treating epilepsy | |
| CN111407850A (en) | Plant selenium sealwort tablet and preparation method thereof | |
| CN110025011A (en) | A kind of Radix Ophiopogonis ginseng lozenge of strengthen immunity | |
| KR101093006B1 (en) | Method for producing functional health food containing bezoar bovis used microbes and the functional health food produced by the same | |
| CN110664905A (en) | Traditional Chinese medicine preparation for expelling wind and clearing away cold and preparation method thereof | |
| CN103989938A (en) | Chitosan composition for preventing and treating diabetes and preparation method of chitosan composition | |
| CN110613793A (en) | Anti-tumor composition and preparation method and application thereof | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220805 |
|
| RJ01 | Rejection of invention patent application after publication |